Year: 2014
Type: review
Abstract: This review summarizes an expanding body of knowledge indicating that failure to resolve inflammation and altered immune processes underlie the development of pulmonary arterial hypertension. The chemokines and cytokines implicated in pulmonary arterial hypertension that could form a biomarker platform are discussed. Pre-clinical studies that provide the basis for dysregulated immunity in animal models of the disease are reviewed. In addition, we present therapies that target inflammatory/immune mechanisms that are currently enrolling patients, and discuss others in development. We show how genetic and metabolic abnormalities are inextricably linked to dysregulated immunity and adverse remodeling in the pulmonary arteries.
Source: Circulation Research
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G1052640295, Pulmonary Hypertension in Genetically Modified Mice, G2421692410, Critical Role for Microvasculature in Airway Transplantation, An Autoimmune Basis for Pulmonary Hypertension, An Autoimmune Basis for Pulmonary Hypertension., G6426351722, Endothelial CD74 in Pulmonary Arterial Hypertension: at the crossroad of Inflammation and Endothelial dysfunction, Elafin Therapy for Pulmonary Arterial Hypertension
OpenAlex ID: W2132001965